|
?:abstract
|
-
Diverse risk factors intercede the outcomes of coronavirus disease 2019 (COVID-19) We conducted this retrospective cohort study with a cohort of 1016 COVID-19 patients diagnosed in May 2020 to identify the risk factors associated with morbidity and mortality outcomes Data were collected by telephone-interview and reviewing records using a questionnaire and checklist The study identified morbidity and mortality risk factors on the 28th day of the disease course The majority of the patients were male (64 1%) and belonged to the age group 25-39 years (39 4%) Urban patients were higher in proportion than rural (69 3% vs 30 7%) Major comorbidities included 35 0% diabetes mellitus (DM), 28 4% hypertension (HTN), 16 6% chronic obstructive pulmonary disease (COPD), and 7 8% coronary heart disease (CHD) The morbidity rate (not-cured) was 6 0%, and the mortality rate (non-survivor) was 2 5% Morbidity risk factors included elderly (AOR = 2 56, 95% CI = 1 31-4 99), having comorbidity (AOR = 1 43, 95% CI = 0 83-2 47), and smokeless tobacco use (AOR = 2 17, 95% CI = 0 84-5 61) The morbidity risk was higher with COPD (RR = 2 68), chronic kidney disease (CKD) (RR = 3 33) and chronic liver disease (CLD) (RR = 3 99) Mortality risk factors included elderly (AOR = 7 56, 95% CI = 3 19-17 92), having comorbidity (AOR = 5 27, 95% CI = 1 88-14 79) and SLT use (AOR = 1 93, 95% CI = 0 50-7 46) The mortality risk was higher with COPD (RR = 7 30), DM (RR = 2 63), CHD (RR = 4 65), HTN (RR = 3 38), CKD (RR = 9 03), CLD (RR = 10 52) and malignant diseases (RR = 9 73) We must espouse programme interventions considering the morbidity and mortality risk factors to condense the aggressive outcomes of COVID-19
-
Diverse risk factors intercede the outcomes of coronavirus disease 2019 (COVID-19). We conducted this retrospective cohort study with a cohort of 1016 COVID-19 patients diagnosed in May 2020 to identify the risk factors associated with morbidity and mortality outcomes. Data were collected by telephone-interview and reviewing records using a questionnaire and checklist. The study identified morbidity and mortality risk factors on the 28th day of the disease course. The majority of the patients were male (64.1%) and belonged to the age group 25-39 years (39.4%). Urban patients were higher in proportion than rural (69.3% vs. 30.7%). Major comorbidities included 35.0% diabetes mellitus (DM), 28.4% hypertension (HTN), 16.6% chronic obstructive pulmonary disease (COPD), and 7.8% coronary heart disease (CHD). The morbidity rate (not-cured) was 6.0%, and the mortality rate (non-survivor) was 2.5%. Morbidity risk factors included elderly (AOR = 2.56, 95% CI = 1.31-4.99), having comorbidity (AOR = 1.43, 95% CI = 0.83-2.47), and smokeless tobacco use (AOR = 2.17, 95% CI = 0.84-5.61). The morbidity risk was higher with COPD (RR = 2.68), chronic kidney disease (CKD) (RR = 3.33) and chronic liver disease (CLD) (RR = 3.99). Mortality risk factors included elderly (AOR = 7.56, 95% CI = 3.19-17.92), having comorbidity (AOR = 5.27, 95% CI = 1.88-14.79) and SLT use (AOR = 1.93, 95% CI = 0.50-7.46). The mortality risk was higher with COPD (RR = 7.30), DM (RR = 2.63), CHD (RR = 4.65), HTN (RR = 3.38), CKD (RR = 9.03), CLD (RR = 10.52) and malignant diseases (RR = 9.73). We must espouse programme interventions considering the morbidity and mortality risk factors to condense the aggressive outcomes of COVID-19.
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}